HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

China Healthcare Weekly (Sep.14) - Trump to Put Restrictions on Chinese Drugs, Sihuan Is Undervalued

Pre-IPO Butong Group (PHIP Updates) - Some Points Worth the Attention

Pre-IPO Zijin Gold (PHIP Updates) - Thoughts on the Business, the Forecast and Valuation Outlook

Pre-IPO Jiangxi Institute of Biological Products-Concerns Behind the Strong Growth and Profitability

Pre-IPO Aux Electric Co (PHIP Updates) - Concerns About Business Model and Valuation Outlook

Pre-IPO GenFleet Therapeutics - The Pipeline Outlook Is Full of Challenges

Pre-IPO Eastenova (Chengdu) Biotechnology- The Commercialization of XH301 May Be Lower than Expected

Equity Capital Markets

GenFleet Therapeutics / Equity Capital Markets

<ul>
<li>GenFleet’s R&amp;D strategy is to layout around the RAS signaling pathway to construct a "RAS therapy matrix" covering multiple RAS mutation types.However, there’re barriers to the development of RAS-targeted therapies.</li>
<li>The factors that suppress valuation include intense competition and potential patent risks. GenFleet’s independent commercialization capability has not been verified. So, a valuation of RMB3-4 billion is a reasonable range.</li>
<li>Considering the sustained popularity of innovative drug IPOs in the Hong Kong stock market, post-IPO valuation of GenFleet depends more on market sentiment, not fundamentals.  </li>
</ul>


GenFleet’s R&amp;D strategy is to layout around the RAS signaling pathway to construct a "RAS therapy matrix" covering multiple RAS mutation types.However, there’re barriers to the development of RAS-targeted therapies.
The factors that suppress valuation include intense competition and potential patent risks. GenFleet’s independent commercialization capability has not been verified. So, a valuation of RMB3-4 billion is a reasonable range.
Considering the sustained popularity of innovative drug IPOs in the Hong Kong stock market, post-IPO valuation of GenFleet depends more on market sentiment, not fundamentals.  


Guangzhou Innogen Pharmaceutical Group (2591 HK)

Pre-IPO GenFleet Therapeutics (PHIP Updates) - Some Points Worth the Attention